Relapsing Refractory Multiple Myeloma Market Size in 7MM is expected to change from 2019-2032

DelveInsight's "Relapsing Refractory Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Relapsing Refractory Multiple Myeloma, historical and forecasted epidemiology as well as the Relapsing Refractory Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover more about therapies set to grab major Relapsing Refractory Multiple Myeloma Market Share @ Relapsing Refractory Multiple Myeloma Market Size- https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Relapsing Refractory Multiple Myeloma Market Report
• As per the viewpoints of Lawrence in a study titled, "Multiple Myeloma Incidence Increasing Worldwide, Especially in the US", the global burden of multiple myeloma has increased uniformly in the last 30 years. In 2016, there were about 130,000 cases of myeloma, translating to an age-standardized incidence rate of 2.1 per 100,000 persons.
• Myeloma Patients Europe highlighted that in Europe about 40,000 people were diagnosed with myeloma in 2015, and this number is predicted to increase to almost 46,000 by 2025. Myeloma can affect adults of any age, but it is much more frequent in people aged over 65 years and in men rather than women.

Relapsing Refractory Multiple Myeloma Overview
Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow.

To explore more information on the latest breakthroughs in the Relapsing Refractory Multiple Myeloma treatment landscape of the report, click here @ Relapsing Refractory Multiple Myeloma Market Outlook- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Refractory Multiple Myeloma Epidemiology Insight
The epidemiology section provides insights into the historical, current, and forecasted Relapsing / Refractory Multiple Myeloma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Relapsing / Refractory Multiple Myeloma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

Relapsing Refractory Multiple Myeloma Epidemiology Segmentation in the 7MM
• Incident cases of Multiple Myeloma (MM) in the 7MM
• Gender-specific Incidence of Multiple Myeloma (MM) in the 7MM
• Age-specific Incidence of Multiple Myeloma (MM) in the 7MM
• Treatable Cases of Multiple Myeloma (MM) Population According to First to Third Line of Treatment
• Treatable Cases of Triple Refractory Multiple Myeloma (MM) in the 7MM

Download the report to understand which factors are driving Relapsing Refractory Multiple Myeloma Epidemiology Trends @ Relapsing Refractory Multiple Myeloma Epidemiological Insights- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Refractory Multiple Myeloma Market Outlook
Relapsing Refractory Multiple Myeloma is a blood cancer affecting plasma cells. The malignant plasma cells show metastases aggravating the problem. In some cases, cancer returns after the treatment or after a period of remission. Most of the patients relapse at some point due to lack of specific cure. Adding worries to myeloma condition, some patients do not respond to the therapy (or sometimes respond to initial treatment, but not to the treatment following a relapse) thereby becoming refractory, and hence known as Relapsing Refractory Multiple Myeloma (RRMM).

Relapsing Refractory Multiple Myeloma Companies include
Allogene Therapeutics, Anaveon AG, Arcellx, Array Biopharma, Bristol-Myers Squibb, Cartesian Therapeutics, Cellectis, Gilead Sciences, Harpoon Therapeutics, Heidelberg Pharma AG, Hrain Biotechnology Co., Ltd., I-MAB Biopharma, Ichnos Sciences, iTeos Therapeutics, Luminary Therapeutics, Novartis, ONK Therapeutics, Oricell Therapeutics, Pfizer, Poseida Therapeutics, Regeneron Pharmaceuticals, Seagen Inc., Sorrento Therapeutics, Takeda, TeneoOne, Trillium Therapeutics Inc., Virtuoso BINco, Inc., Xencor, and others.

Relapsing Refractory Multiple Myeloma Emerging Drugs

Mezigdomide: Bristol-Myers Squibb
Cereblon E3 ligase modulators (CELMoD) are a class of oral immunomodulatory therapeutics that are designed to stimulate the immune system and directly kill cancer cells by inducing the degradation of tumor-promoting proteins. Bristol Myers Squibb is investigating two novel CELMoD agents, mezigdomide and iberdomide, for multiple myeloma that were intentionally designed to improve upon the demonstrated efficacy of the IMiD® agents, along with manageable tolerability, ease of administration, and the potential to improve patient outcomes. These agents co-opt cereblon to induce degradation of target proteins Ikaros and Aiolos, which inhibits tumor cell proliferation, promote tumor cell death, and induce immune-stimulatory effects. Mezigdomide induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells. Based on Phase I/II interim results, mezigdomide, in combination with weekly DEX (40 mg; 20 mg if >75 years of age), showed promising efficacy in a highly refractory patient population. Mezigdomide is currently being investigated in Phase III stage of development for the treatment of Relapsed or Refractory Multiple Myeloma.
 
Iopofosine: Cellectar Biosciences, Inc.
Iopofosine is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.

ORIC-533: ORIC Pharmaceuticals
ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Multiple Myeloma.

To know more about Relapsing Refractory Multiple Myeloma Therapies options, visit @ Relapsing Refractory Multiple Myeloma Therapeutics Market- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Relapsing Refractory Multiple Myeloma
3. Competitive Intelligence Analysis for Relapsing Refractory Multiple Myeloma
4. Relapsing Refractory Multiple Myeloma: Market Overview at a Glance
5. Relapsing Refractory Multiple Myeloma: Disease Background and Overview
6. Patient Journey
7. Relapsing Refractory Multiple Myeloma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Relapsing Refractory Multiple Myeloma Unmet Needs
10. Key Endpoints of Relapsing Refractory Multiple Myeloma Treatment
11. Relapsing Refractory Multiple Myeloma Marketed Products
12. Relapsing Refractory Multiple Myeloma Emerging Therapies
13. Relapsing Refractory Multiple Myeloma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Relapsing Refractory Multiple Myeloma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Learn more about the Relapsing Refractory Multiple Myeloma Pipeline Therapies in clinical trials @ Relapsing Refractory Multiple Myeloma SWOT Analysis, Unmet Needs, Reimbursement, and Patient Journey- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.